Evidence map›Paper›PMID 42351108›Full record

ArticleJournal of nanobiotechnology2026

A magnetic resonance imaging-guided drug delivery system for premetastatic niche theranostics and colorectal cancer liver metastasis intervention.

Wangping Luo, Xiaoyan Yang, Yining Wang, Jianxia Xu, Yijie Lou, Jiayi Chen, Jue Hou, Xiaojie Wang, Yuanfei Lu, Jin Mao and 3 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of nanobiotechnology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Wangping LuoDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Xiaoyan YangDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Yining WangDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Jianxia XuDepartment of Radiology, The Second Affiliated Hospital of Zhejiang, Chinese Medical University, 318 Chaowang Road, Hangzhou, 310005, Zhejiang Province, People's Republic of China.
Yijie LouThe First Affiliated Hospital of Zhejiang Chinese Medical University, Zhejiang Provincial Hospital of Chinese Medicine, Hangzhou, 310053, Zhejiang Province, People's Republic of China.
Jiayi ChenCollege of Biomedical Engineering & Instrument Science, Zhejiang University, Hangzhou, 310028, People's Republic of China.
Jue HouDepartment of Chemistry, Zhejiang University, Hangzhou, 310028, People's Republic of China.
Xiaojie WangDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Yuanfei LuDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Jin MaoDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China.
Guping TangDepartment of Chemistry, Zhejiang University, Hangzhou, 310028, People's Republic of China.
Hongzhen BaiDepartment of Chemistry, Zhejiang University, Hangzhou, 310028, People's Republic of China. hongzhen_bai@zju.edu.cn.
Risheng YuDepartment of Radiology, Second Affiliated Hospital, School of Medicine, Zhejiang University, 88 Jiefang Road, Hangzhou, 310009, Zhejiang Province, People's Republic of China. risheng-yu@zju.edu.cn.ORCID https://orcid.org/0000-0003-0554-9484

Funding

the Co-construction Project of Zhejiang Administration of Traditional Chinese Medicine GZY-ZJ-KJ-2303the Huadong Medicine Joint Fund of the Zhejiang Provincial Natural Science Foundation of China LHDMD25H300001the National Natural Science Foundation of China 22575214the National Natural Science Foundation of China 82171998the National Natural Science Foundation of China 82402343the Natural Science Foundation of Zhejiang Province LZ26H180001
6 · The paper itself

Abstract

Colorectal cancer liver metastasis (CRLM) poses a major challenge in cancer theranostics, in which hepatic stellate cell (HSC) activation participates in fibrosis progression and colorectal cancer (CRC) cell recruitment, catalyzing the formation of fibrosis-concomitant premetastatic niche (PMN). Targeting the crosstalk between activated HSCs (aHSCs) and CRC cells, we develop a bioengineered, mesoporous superparamagnetic iron oxide nanoparticle (mSPIONP)-based theranostic nano-system (mSPIONP-Cur@eCM). Camouflaged with CXC chemokine receptor type 4 (CXCR4)-overexpressing CRC cytomembranes, this nano-system exhibits a dual PMN-targeting function, exerting a homologous recognition to CRC cells and anchors to aHSCs with a high secretion of stromal cell-derived factor-1 (SDF-1). Its mSPIONP-Cur core affords not only T2-weighted magnetic resonance imaging (MRI) but also curcumin (Cur) delivery, initiating liver fibrosis detection and metastasis foci delineation, simultaneously blocking the HSC-CRC cell crosstalk by amplifying Cur's therapeutic effect. Verified in fibrosis and CRLM models, mSPIONP-Cur@eCM exhibits great potential for suppressing the fibrosis-concomitant PMN and intervening the CRLM progression.

Indexed as

Colorectal NeoplasmsDrug Delivery SystemsLiver NeoplasmsMagnetic Resonance ImagingTheranostic NanomedicineAnimalsCell Line, TumorChemokine CXCL12CurcuminHepatic Stellate CellsHumansMagnetic Iron Oxide NanoparticlesMagnetite NanoparticlesMiceReceptors, CXCR4Chemokine CXCL12CurcuminMagnetite NanoparticlesReceptors, CXCR4Drug DeliveryHepatic Stellate cellMagnetic Resonance ImagingPremetastatic Niche

Identifiers

PMID42351108
PMCPMC13560219

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.